LONDON (Reuters) - Biogen Idec has won regulatory protection for its top-selling multiple sclerosis drug Tecfidera in Europe, paving the way for its launch in markets that could account for a large proportion of future sales.
Reported by Reuters 12 hours ago.
↧
